Hemophilia A FAQ
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

Released: January 14, 2022

Expiration: January 13, 2023

Miguel A. Escobar
Miguel A. Escobar, MD
Mark T Reding
Mark T Reding, MD
Guy Young
Guy Young, MD

Activity

Progress
1
Course Completed

In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include:

  • Which patients should have pharmacokinetic-guided therapy?
  • Toxicities with PEGylated extended half-life products
  • Factor VIII and bone health
  • Factor VIII peaks, thrombotic risk, and cardiovascular disease
  • Choosing between extended half-life products and emicizumab for active patients
  • Role of fitusiran in the treatment paradigm if approved